SCHEMBL20560892

SCHEMBL20560892

Clc1nc(-c2ccccc2)nc(-c2cccc(-c3cccc(-c4ccccc4)c3)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 6/20 0.50
HPGD P15428 6/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 5/20 0.47
HTT P42858 1/20 0.47
GP6 Q9HCN6 1/20 0.46
MAPT P10636 4/20 0.44
KDM4E B2RXH2 4/20 0.44
GLA P06280 2/20 0.44
KMO O15229 1/20 0.42
ADORA2A P29274 2/20 0.42
ADORA1 P30542 2/20 0.42
POLB P06746 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2B P29275 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30776051 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL30478982 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL16615119 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL29518847 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL29375767 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL30383694 1.00 MEN1 (0.50) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL24741475 0.98 MEN1 (0.48) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL20942804 0.98 MEN1 (0.48) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL21304683 0.98 MEN1 (0.48) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL20870346 0.98 MEN1 (0.48) MEN1KMT2AALDH1A1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11903311-B2 Heterocyclic compound and organic light emitting device comprising the same LG CHEM, LTD. (KR) 2024-02-13 US disclosed
US-20230139045-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE SAMSUNG SDI CO., LTD. (KR) 2023-05-04 US disclosed
US-20230139045-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE SAMSUNG SDI CO., LTD. (KR) 2023-05-04 US disclosed
EP-3480194-B1 HETEROCYCLIC COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES USING SAME LG CHEMICAL LTD (KR) 2021-09-08 EP disclosed
EP-3480194-A1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME LG Chem, Ltd. (KR) 2019-05-08 EP disclosed
US-20180337348-A1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD. (KR) 2018-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11903311-B2 Heterocyclic compound and organic light emitting device comprising the same CYP1A1, CYP1B1, CHRM1 MEN1 533/4885KMT2A 1845/4885ALDH1A1 173/4885
US-20230139045-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE OXER1, OCIAD1, OR10J3 MEN1 2142/4885KMT2A 4009/4885ALDH1A1 66/4885
US-20180337348-A1 NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CRY2, ORC3 MEN1 909/4885KMT2A 645/4885ALDH1A1 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.